Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Buy
59
WXXWY Quote, Financials, Valuation and Earnings
Last price:
$4.47
Seasonality move
:
-6.65%
Day range:
$4.45 - $4.50
52-week range:
$2.58 - $7.87
Dividend yield:
0%
P/E ratio:
26.86x
P/S ratio:
4.05x
P/B ratio:
1.65x
Volume:
8.7K
Avg. volume:
53.4K
1-year change:
-35.26%
Market cap:
$9.2B
Revenue:
$2.4B
EPS (TTM):
$0.17
Analysts' Opinion
-
Consensus RatingWuXi Biologics (Cayman) has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, WuXi Biologics (Cayman) has an estimated downside of -- from its current price of $4.48.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $4.48.
Fair Value
-
According to the consensus of 0 analysts, WuXi Biologics (Cayman) has -- downside to fair value with a price target of -- per share.
WXXWY vs. S&P 500
-
Over the past 5 trading days, WuXi Biologics (Cayman) has overperformed the S&P 500 by 0.12% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
WuXi Biologics (Cayman) does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
WuXi Biologics (Cayman) has grown year-over-year revenues for 0 quarters straight. In the most recent quarter WuXi Biologics (Cayman) reported revenues of --.
Earnings Growth
-
WuXi Biologics (Cayman) has grown year-over-year earnings for 0 quarters straight. In the most recent quarter WuXi Biologics (Cayman) reported earnings per share of --.
Enterprise value:
8.7B
EV / Invested capital:
--
Price / LTM sales:
4.05x
EV / EBIT:
16.54x
EV / Revenue:
3.67x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-194.22x
Price / Operating cash flow:
112.84x
Enterprise value / EBITDA:
16.54x
Gross Profit (TTM):
$919.7M
Return On Assets:
4.8%
Net Income Margin (TTM):
15.38%
Return On Equity:
6.19%
Return On Invested Capital:
5.86%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-26 | 2023-12-26 | 2023-12-26 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $3.4B | $3.1B | $2.5B | $2.7B | |
| Total Assets | $2.9B | $6.7B | $7.1B | $7.2B | $7.7B | |
| Current Liabilities | $447.7M | $841.7M | $1.3B | $1.1B | $936.7M | |
| Total Liabilities | $979.4M | $1.5B | $1.8B | $1.8B | $1.6B | |
| Total Equity | $1.9B | $5.2B | $5.3B | $5.4B | $6.1B | |
| Total Debt | $416.1M | $500.3M | $429.6M | $388.1M | $296.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-26 | 2023-12-26 | 2023-12-26 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
WXXWY
Sector
Market Cap
$9.2B
$46.1M
Price % of 52-Week High
56.93%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
5.52%
-0.6%
1-Year Price Total Return
-35.26%
-30.52%
Beta (5-Year)
0.434
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$4.39
200-day SMA
Buy
Level
$3.50
Bollinger Bands (100)
Buy
Level
2.99 - 4.53
Chaikin Money Flow
Buy
Level
1.8M
20-day SMA
Buy
Level
$4.31
Relative Strength Index (RSI14)
Buy
Level
56.62
ADX Line
Buy
Level
6.47
Williams %R
Neutral
Level
-65
50-day SMA
Buy
Level
$4.20
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-6.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.5476)
Buy
CA Score
(Annual)
Level (0.988)
Buy
Beneish M-Score
(Annual)
Level (-2.35)
Sell
Momentum Score
Level (1)
Buy
Ohlson Score
Level (-2.9025)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
Stock Forecast FAQ
In the current month, WXXWY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The WXXWY average analyst price target in the past 3 months is --.
-
Where Will WuXi Biologics (Cayman) Stock Be In 1 Year?
According to analysts, the consensus estimate is that WuXi Biologics (Cayman) share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About WuXi Biologics (Cayman)?
Analysts are divided on their view about WuXi Biologics (Cayman) share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that WuXi Biologics (Cayman) is a Sell and believe this share price will rise from its current level to --.
-
What Is WuXi Biologics (Cayman)'s Price Target?
The price target for WuXi Biologics (Cayman) over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is WXXWY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for WuXi Biologics (Cayman) is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of WXXWY?
You can purchase shares of WuXi Biologics (Cayman) via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase WuXi Biologics (Cayman) shares.
-
What Is The WuXi Biologics (Cayman) Share Price Today?
WuXi Biologics (Cayman) was last trading at $4.47 per share. This represents the most recent stock quote for WuXi Biologics (Cayman). Yesterday, WuXi Biologics (Cayman) closed at $4.48 per share.
-
How To Buy WuXi Biologics (Cayman) Stock Online?
In order to purchase WuXi Biologics (Cayman) stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
